Aarti Drugs has received Establishment Inspection Report (EIR) from USFDA concluding the inspection as closed for its API manufacturing facility located at Plot No-E-22, MIDC, Tarapur, Maharashtra.
UFDA has determined that the inspection classification of this facility is voluntary action indicated (VAI). Based on this inspection, this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
